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Feature Articles 
Heart Failure: New Questions and Insights About an Old Foe 
Why devote an issue of a medical joumal to aspects of heart failure at this time? Heart failure, after all, has been rec-
ognized for centuries, and the literature is replete with articles 
involving a myriad of issues relating to heart failure. 
Contrary to the situation with coronary artery disease, the in-
cidence of heart failure is increasing in this country. In 1970 an 
estimated 500,000 patients were hospitalized with a diagnosis of 
heart failure. This figure doubled in the next decade. Each year 
an additional 400,000 individuals are diagnosed as having heart 
failure, with an annual mortality rate of 10% to 20% (1). 
Many reasons account for this increase. Life expectancy in 
America has increased for all population groups. This is partly 
related to improved living standards, but the development of 
therapeutic modalities, newer and more potent antibiotics, 
management of certain malignancies, and improvements in the 
management of cardiovascular disease undoubtedly have con-
tributed. Patients with hypertension, coronary artery disease, 
cardiomyopathy, and valvular heart disease are managed to a 
point of chronicity that was previously considered unattainable. 
In this edition of the Henry Ford Hospital Medical Journal 
many important issues relating to the understanding, causes, 
and newer management modalities of heart failure are dis-
cussed. Advances in understanding the pathophysiology of heart 
failure are summarized (2). These advances have spurred the 
whole spectrum of clinical and bench cardiological research 
which is cunently conducted at a biochemical and subcellular 
level. The possible role of platelets in the thromboembolic com-
plications of patients with heart failure is also discussed (3). 
As our ability to treat heart failure improves, signs of conges-
tion are seen less frequently, even in patients with severe pump 
dysfunction. Problems associated with this change in the man-
ifestation of myocardial dysfunction are reported by Jafri et al 
(4). Echocardiography is extremely useful and in many in-
stances complements the clinical evaluation of patients with 
heart failure. Alam (5) discusses the role of this noninvasive 
procedure along with the important differential features of the 
various causes of heart failure. 
Garcia and Alam (6) highlight the restrictive cardiomyopa-
thies, particularly amyloid heart disease which is more fre-
quently diagnosed premortem because of the routine availability 
of echocardiography. The protean manifestations of this condi-
tion are also noted. A high index of suspicion is necessary to 
make the diagnosis, and echocardiography should be consid-
ered whenever the presentation of heart failure is somewhat 
atypical, especially in elderly patients. 
Sudden death is an important cause of demise in this patient 
population. The majority of patients with heart failure still re-
ceive digoxin and diuretic therapy. Rosman et al (7) discuss the 
possibility of electrolyte imbalance, particularly potassium ab-
normalities, as a contributing factor to sudden death in these 
individuals. 
In the realm of patient management, classic therapeutic inter-
ventions such as digitalis still play an important role. With better 
understanding of the effects of acute and chronic digitalis ther-
apy, a more rational approach for its use is possible (8). Gold-
stein (9) reviews the apparent paradox of using beta-blockade in 
selected patients with heart failure and the theory behind such 
use. A host of inotropic agents have been recently introduced 
into the therapeutic armamentarium for the management of 
heart failure. Their mechanism of action, benefits, and disad-
vantages are presented by Jafri and Bristol (10). 
Controversy exists regarding the timing of surgery in the 
management of patients with valvular disease. Early surgery has 
been recommended to prevent ineversible left ventricular dys-
function. Lee et al (11) report the results following aortic valve 
replacement in patients with aortic stenosis or regurgitation. Im-
provement in ventricular function generally can be expected, al-
though in certain instances improvement may be delayed. 
Finally, stemming from advances in renal transplantation and 
the improved ability to control rejection, cardiac transplantation 
has advanced from an experimental procedure to that of an 
important therapeutic option in patients with end-stage heart 
failure (12), 
This edirion of the Journal is not intended to be a compre-
hensive review of all the advances or changes in the patho-
physiology, diagnosis, or management of patients with heart 
failure. Neither is it our intent to supply all the answers. How-
ever, we pinpoint several areas of this vast subject where ad-
vances have changed prior dogma and also attempt to place some 
of the issues in perspective. Each new insight or advance often 
produces further complications and poses more problems. At 
best we can hope to improve patients' quality of life and perhaps 
extend their survival by better understanding the disease process 
and its management. 
Jeffrey B. Lakier, MD 
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